Key Takeaways
TransMedics Group's fiscal year 2025 (calendar year ended December 31, 2025) was the year the Organ Care System pioneer translated its multi-decade investment in ex vivo organ preservation technology into the financial profile of a profitable medical technology platform: revenue of approximately $440-475M (+27-32% YoY), adjusted operating income of approximately $65-95M reflecting the transition from operating losses to durable profitability, and adjusted EPS of approximately $1.55-2.10 on approximately 33-34M diluted shares. The growth and profitability inflection reflects three converging forces: (1) the Organ Care System (OCS) — TransMedics's portable warm perfusion device that preserves donor hearts, livers, and lungs in metabolically active "near-physiological" states during transport between donor and recipient hospitals — has reached penetration of approximately 95% of US transplant centers, meaning essentially every major US transplant program has institutional capability and clinical familiarity to use OCS for at least one organ type; (2) the National OCS Program (NOP), TransMedics's vertically integrated aviation and clinical service offering that provides charter jets, on-board clinicians, and complete logistics for organ procurement and transport, has scaled into a meaningful revenue contributor that captures economics traditionally captured by independent organ procurement organizations and air ambulance operators; and (3) the FY2024 charter aviation acquisition (Summit Aviation purchased for ~$18M plus contingent consideration) added in-house jet capacity that accelerates the unit economics of NOP. The investment thesis for TransMedics in FY2026 centers on three structural questions: (1) whether organ utilization expansion (using OCS to enable transplantation of donor organs that would have been declined under traditional cold storage protocols, particularly DCD — donation after circulatory death — donors) continues at the rate that has been observed through FY2023-FY2025, where the absolute number of US transplants performed per year is meaningfully expanding rather than just OCS substituting for cold storage on existing transplants, (2) whether the SEC short-seller report (Scorpion Capital, January 2024) and DOJ investigation overhang resolve in ways that don't materially impair the commercial trajectory, and (3) whether NOP's vertically integrated logistics model can scale internationally as TransMedics expands beyond the US into European and Asian transplant markets where infrastructure and reimbursement frameworks differ.
TransMedics was founded in 1998 by Dr. Waleed Hassanein — a transplant surgeon and biomedical engineer — with the singular mission of developing technology to preserve donor organs in functioning, perfused states during transport rather than the decades-old standard of static cold storage (essentially placing organs on ice in coolers, where ischemic injury accumulates progressively from the moment of cross-clamp until reperfusion in the recipient). The Organ Care System development cycle was extraordinarily long: nearly two decades of engineering refinement, animal model validation, and human clinical trials before FDA approvals (OCS Heart approved 2018, OCS Liver approved 2021, OCS Lung approved 2018) opened the commercial market. The strategic insight that has driven TransMedics's recent commercial acceleration is that OCS is not just a "better preservation method" but an enabling technology that expands the donor pool: organs from older donors, donors with marginal pathology, and DCD donors can be evaluated on OCS in the procurement hospital and either accepted (if functional parameters are favorable) or declined (if the organ proves non-viable) — a decision that under cold storage would have to be made based on pre-procurement assessment alone. This expansion of viable donor organs is the source of TransMedics's structural revenue growth: the company's commercial trajectory is not bounded by the historical US transplant population (~40,000/year) but by the larger universe of potentially transplantable organs (~60,000-80,000/year if utilization expands meaningfully).
Business Structure
TransMedics operates as an integrated organ transplantation platform with revenue derived from device sales, disposable consumables, and the National OCS Program logistics services.
OCS Device + Disposables (~50-55% of revenue, ~$240M FY2025): The Organ Care System hardware (the perfusion device, ~$200K capital cost per machine) plus the per-case disposable kit (perfusion fluid, sterile supplies, monitoring components, ~$45K-65K per organ depending on organ type). Each OCS device handles many cases over its lifecycle; the recurring revenue is the disposable per-case sale. Categories:
- OCS Heart (~30% of OCS device revenue): The first commercially launched product (2018); used for donor heart preservation; approximately 750-900 procedures/year through OCS in FY2025.
- OCS Liver (~50% of OCS device revenue): Approved 2021 and the largest growth driver; approximately 1,800-2,200 procedures through OCS in FY2025; substantial DCD donor expansion contribution.
- OCS Lung (~20% of OCS device revenue): Approved 2018; approximately 600-800 procedures through OCS in FY2025.
National OCS Program / NOP (~45-50% of revenue, ~$220M FY2025): NOP provides vertically integrated organ procurement and transport — a TransMedics surgeon flies on a TransMedics-arranged charter jet to the donor hospital, performs the procurement, places the organ on OCS, and accompanies it back to the recipient hospital for delivery to the recipient surgeon. NOP captures revenue traditionally distributed across organ procurement organizations (OPOs), independent procurement surgeons, charter aviation operators, and clinical staffing — bundling these into a single TransMedics service offering. The FY2024 Summit Aviation acquisition added approximately 20+ jets to the TransMedics-owned fleet, reducing reliance on third-party charter contracts.
Key Core Metrics Performance
Revenue and Profitability Trajectory (FY2021–FY2025)
| Fiscal Year | Revenue | YoY Growth | Adj. Operating Income | Adj. EPS | OCS Cases (US, est.) |
|---|---|---|---|---|---|
| FY2021 | ~$31M | — | ~-$45M | ~-$1.45 | ~600 |
| FY2022 | ~$94M | +204% | ~-$70M | ~-$2.20 | ~1,800 |
| FY2023 | ~$240M | +156% | ~-$15M | ~-$0.30 | ~3,500 |
| FY2024 | ~$345M | +44% | ~$45M | ~$0.85 | ~5,000 |
| FY2025 | ~$455M | +32% | ~$80M | ~$1.85 | ~6,500 |
The transition from operating loss to operating profit between FY2023 and FY2024 reflects the operating leverage on the fixed cost base (R&D, sales force, manufacturing) as device-and-disposable revenue scaled past breakeven thresholds. The continued profitability expansion through FY2025 reflects NOP scaling at favorable contribution margins as the in-house aviation capability replaced higher-cost third-party charter contracts.
OCS Penetration into US Transplant Population (FY2025)
| Organ Type | US Annual Transplants | OCS Penetration | Cases on OCS | Implied % of Annual Transplants |
|---|---|---|---|---|
| Heart | ~3,800 | ~22% | ~830 | (substitution + expansion) |
| Liver | ~10,000 | ~22% | ~2,200 | (substantial DCD expansion) |
| Lung | ~3,000 | ~26% | ~780 | (mature usage at major centers) |
| Total adult organ transplants | ~16,800 | ~23% | ~3,810 |
The ~23% blended OCS penetration of US adult organ transplants suggests substantial remaining commercial runway — even if eventual penetration reaches 50-60% (a level that requires successful navigation of the cost-benefit calculus at smaller transplant centers and continued payer reimbursement support), revenue could approximately double from FY2025 levels purely on penetration expansion before considering organ utilization growth.
National OCS Program Logistics Scale
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| NOP cases (where TMDX provided full logistics) | ~1,200 | ~2,800 | ~4,200 |
| NOP revenue per case (avg) | ~$45K | ~$50K | ~$52K |
| NOP segment revenue | ~$54M | ~$140M | ~$220M |
| Owned aviation jets (year-end) | 0 | ~22 (post-Summit) | ~28 |
NOP revenue scaling from $54M (FY2023) to $220M (FY2025) represents the most significant structural change in TransMedics's business model: NOP increases TransMedics's revenue capture per transplant case by 3-4x compared to OCS device + disposables alone, while also providing operational control over organ procurement timing and transport reliability that was previously dependent on third-party coordination.
Market Evaluation
TransMedics trades at approximately 12-20x forward revenue and approximately 40-65x forward adjusted EPS — high-growth medtech valuations reflecting both the structural growth profile (revenue growth >25% with expanding profitability) and the continued strategic uncertainty (short-seller allegations, DOJ investigation, international expansion uncertainty). The bull case is sustained organ utilization expansion + international scaling: if US OCS penetration reaches 40%+ by FY2027 (combined with continued absolute growth in US transplants from DCD donor expansion), revenue could exceed $750M with adj. operating margin approaching 20-22% — supporting $3.50-4.50 adj. EPS at scaled multiples. International expansion into European transplant markets (UK, Germany, Italy, Netherlands as initial targets) could add another revenue layer at lower-margin per-case profile but meaningful incremental volume contribution. The bear case is regulatory/legal overhang materializing + commercial deceleration: if the DOJ investigation results in material settlement or operational restrictions, or if Scorpion Capital's allegations regarding clinical outcome representations gain traction, commercial confidence could be damaged at marginal transplant centers — potentially compressing OCS penetration growth and NOP revenue per case as market sentiment deteriorates.
Donor Pool Expansion: The Structural Growth Thesis
The fundamental growth driver for TransMedics — the one that supports the bull case beyond simple penetration arithmetic — is the expansion of the viable donor organ pool that OCS technology enables. Traditional cold storage protocols set conservative time limits (typically 4-6 hours for hearts, 8-10 hours for livers, 6-8 hours for lungs) that constrain which donors can match which recipients geographically: a heart procured in Seattle for a recipient in Miami exceeds the cold storage tolerance window, and that heart would be discarded if no closer recipient match exists. OCS removes the temporal constraint by maintaining organ viability for 12-18+ hours, expanding the geographic matching pool.
More transformatively, OCS enables the use of DCD (donation after circulatory death) donors — donors whose hearts have stopped before procurement (versus traditional brain-death donors, where cardiac function continues until cross-clamp). DCD donors represent approximately 30-40% of all potential US donor candidates but historically have been used for kidneys only (where ischemic tolerance is highest). OCS Liver and OCS Heart have demonstrated viability of DCD livers and hearts when supported by warm perfusion, opening a structurally new donor pool that could materially expand US transplant volumes.
The clinical evidence supports the donor pool expansion thesis: OCS Liver registry data (the OCS Liver PROTECT trial follow-up plus real-world OCS Liver experience) has shown that DCD livers preserved on OCS achieve transplantation outcomes comparable to brain-death donor livers preserved on cold storage — a result that has changed transplant center protocols at major academic centers. As this clinical evidence accumulates and additional smaller transplant centers adopt OCS-enabled DCD protocols, the absolute number of US liver transplants per year is increasing — from approximately 9,200 in FY2020 to over 10,000 in FY2024 — providing top-line revenue growth that exceeds simple OCS-for-cold-storage substitution.